<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860883</url>
  </required_header>
  <id_info>
    <org_study_id>02.18</org_study_id>
    <nct_id>NCT03860883</nct_id>
  </id_info>
  <brief_title>Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma</brief_title>
  <acronym>MelMarT-II</acronym>
  <official_title>Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melanoma and Skin Cancer Trials Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuyderland Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melanoma and Skin Cancer Trials Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a primary invasive melanoma are recommended to undergo excision of the primary&#xD;
      lesion with a wide margin. There is evidence that less radical margins of excision may be&#xD;
      just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of&#xD;
      the primary lesion for adult patients with stage II primary invasive cutaneous melanomas&#xD;
      (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins&#xD;
      is expected to improve patient quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine whether there is a difference in disease-free survival rates for&#xD;
      patients with primary cutaneous melanoma with Breslow thickness &gt; 2mm or 1-2mm with&#xD;
      ulceration (pT2b-pT4b, AJCC 8th edition), treated with either a 1cm excision margin or 2cm&#xD;
      margin. The study is designed to be able to prove or disprove that there is no difference in&#xD;
      risk of the tumour recurring around the scar or anywhere else in the body between the two&#xD;
      groups of patients. If the study shows no risk of tumour recurrence then we will also be able&#xD;
      to determine how much of an impact the narrower excision has on patients in terms of improved&#xD;
      quality of life and reduced side effects from the surgery and melanoma disease. This trial&#xD;
      will also evaluate and determine the economic impact of narrower excision margins on the&#xD;
      health services and society in general.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2034</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>0-60 months</time_frame>
    <description>Time from randomisation to clinically, histologically or radiologically confirmed recurrence of melanoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Recurrence</measure>
    <time_frame>Day 0-Trial Completion (max. 120 months)</time_frame>
    <description>Time from randomisation to any clinically, histologically or radiologically confirmed local recurrence of melanoma including satellite lesions and in transit metastases to regional draining lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Disease-Free Survival</measure>
    <time_frame>Day 0-Trial Completion (max. 120 months)</time_frame>
    <description>Time from randomisation to any clinically, histologically or radiologically confirmed distant recurrence of melanoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanoma-Specific Survival</measure>
    <time_frame>Day 0-Trial Completion (max. 120 months)</time_frame>
    <description>Time from randomisation to death due to melanoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Day 0-Trial Completion (max. 120 months)</time_frame>
    <description>Time from randomisation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanoma-specific Quality of Life: FACT-M questionnaire</measure>
    <time_frame>Baseline, 3, 6, 12 &amp; 24 months</time_frame>
    <description>Measured by FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire - It consists of two subsections: The FACT-G subsection is a 27-item compilation of general questions divided into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. It is considered appropriate for use with patients with any form of cancer. The Melanoma Surgery Subscale evaluates melanoma-specific symptoms such as surgical morbidity and side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain: PainDetect questionnaire</measure>
    <time_frame>Baseline, 3, 6, 12 &amp; 24 months</time_frame>
    <description>Measured by PainDetect questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life: EQ-5D-5L questionnaire</measure>
    <time_frame>Baseline, 3, 6, 12 &amp; 24 months</time_frame>
    <description>Measured by EuroQoL EQ-5D-5L questionnaire - This tool contains 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery Related Adverse Events</measure>
    <time_frame>Up to 90 days from the date of surgery</time_frame>
    <description>The following surgical adverse events will be recorded from the time of surgery to 90 days following surgery (inclusive):&#xD;
wound dehiscence&#xD;
seroma/haematoma&#xD;
haemorrhage&#xD;
infection&#xD;
skin graft failure&#xD;
necrosis of flap used for reconstruction&#xD;
deep venous thrombosis&#xD;
urinary tract infection&#xD;
pneumonia&#xD;
cardiac complications&#xD;
lymphoedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Within 1 year from randomisation</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a participant administered a treatment which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the treatment timing, whether or not considered related to the treatment. An AE is any adverse change (developing or worsening) from the participant's pre-treatment condition, including intercurrent illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Evaluation</measure>
    <time_frame>Baseline, 3, 6, 12 &amp; 24 months</time_frame>
    <description>Data collected for economic analysis will be from hospital notes, MBS and PBS data (Australia) and patient reported outcome measures (including an employment questionnaire) at baseline, 3, 6, 12 and 24 months and at melanoma recurrence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2998</enrollment>
  <condition>Cutaneous Melanoma, Stage II</condition>
  <arm_group>
    <arm_group_label>Arm A (Wide Local Excision = 1cm Margin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Wide Local Excision = 2cm Margin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Local Excision = 1cm Margin</intervention_name>
    <description>A wide local excision involves removing an extra &quot;safety margin&quot; of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.</description>
    <arm_group_label>Arm A (Wide Local Excision = 1cm Margin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Local Excision = 2cm Margin</intervention_name>
    <description>A wide local excision involves removing an extra &quot;safety margin&quot; of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.</description>
    <arm_group_label>Arm B (Wide Local Excision = 2cm Margin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a stage II primary invasive cutaneous melanoma with Breslow&#xD;
             thickness &gt; 2mm without ulceration, or &gt;1mm (with ulceration only) (pT2b-pT4b, AJCC&#xD;
             8th edition) as determined by diagnostic biopsy (narrow excision, incision or punch&#xD;
             biopsy) and subsequent histopathological analysis.&#xD;
&#xD;
          2. Must have a primary melanoma that is cutaneous (including head, neck, trunk,&#xD;
             extremity, scalp, palm, or sole).&#xD;
&#xD;
          3. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary&#xD;
             melanoma.&#xD;
&#xD;
          4. Staging sentinel node biopsy must be completed within three months (92 days) of the&#xD;
             original diagnosis.&#xD;
&#xD;
          5. Patients must be 18 years or older at time of consent.&#xD;
&#xD;
          6. Patient must be able to give informed consent and comply with the treatment protocol&#xD;
             and follow-up plan.&#xD;
&#xD;
          7. Life expectancy of at least 5 years from the time of diagnosis, not considering the&#xD;
             melanoma in question, as determined by the PI.&#xD;
&#xD;
          8. Patients must have an ECOG performance score between 0 and 1.&#xD;
&#xD;
          9. A survivor of prior cancer is eligible provided that ALL of the following criteria are&#xD;
             met and documented:&#xD;
&#xD;
               -  The patient has undergone potentially curative therapy for all prior&#xD;
                  malignancies,&#xD;
&#xD;
               -  There has been no evidence of recurrence of any prior malignancies for at least&#xD;
                  FIVE years (except for successfully treated cervical or non-melanoma skin cancer&#xD;
                  with no evidence of recurrence), and&#xD;
&#xD;
               -  The patient is deemed by their treating physician to be at low risk of recurrence&#xD;
                  from previous malignancies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown&#xD;
             malignant potential'.&#xD;
&#xD;
          2. Patient has already undergone wide local excision at the site of the primary index&#xD;
             lesion.&#xD;
&#xD;
          3. Patient unable or ineligible to undergo staging sentinel lymph node biopsy of the&#xD;
             primary index lesion.&#xD;
&#xD;
          4. Desmoplastic or neurotropic melanoma.&#xD;
&#xD;
          5. Microsatellitosis as per AJCC 8th edition definition&#xD;
&#xD;
          6. Subungual melanoma&#xD;
&#xD;
          7. Patient has already undergone a local flap reconstruction of the defect after excision&#xD;
             of the primary and determination of an accurate excision margin is impossible.&#xD;
&#xD;
          8. History of previous or concurrent (i.e., second primary) invasive melanoma.&#xD;
&#xD;
          9. Melanoma located distal to the metacarpophalangeal joint, on the tip of the nose, the&#xD;
             eyelids or on the ear, genitalia, perineum or anus, mucous membranes or internal&#xD;
             viscera.&#xD;
&#xD;
         10. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit,&#xD;
             regional, or distant metastatic melanoma.&#xD;
&#xD;
         11. Patient has undergone surgery on a separate occasion to clear the lymph nodes of the&#xD;
             probable draining lymphatic field, including sentinel lymph node biopsy, of the index&#xD;
             melanoma.&#xD;
&#xD;
         12. Any additional solid tumour or hematologic malignancy during the past 5 years except&#xD;
             T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical&#xD;
             cancer.&#xD;
&#xD;
         13. Melanoma-related operative procedures not corresponding to criteria described in the&#xD;
             protocol.&#xD;
&#xD;
         14. Planned adjuvant radiotherapy to the primary melanoma site after Wide Local Excision&#xD;
             is not permitted as part of the protocol and any patients given this treatment would&#xD;
             be excluded from the study.&#xD;
&#xD;
         15. History of organ transplantation.&#xD;
&#xD;
         16. Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at&#xD;
             enrolment or within 6 months prior to enrolment.&#xD;
&#xD;
        Pregnancy is not a specific exclusion criterion for this trial, though it may not be&#xD;
        clinically appropriate to perform a wide excision and sentinel node biopsy until the&#xD;
        pregnancy has been completed, which is likely to exclude the patient due to violation of&#xD;
        inclusion criterion 4. We would advise careful counselling of the patient prior to&#xD;
        enrolling the patient, which would include a discussion at the treating centre's&#xD;
        multidisciplinary team meeting or tumour board. We would strongly advise contacting the&#xD;
        central trial office to discuss the case prior to enrolling on the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Henderson</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Moncrieff</last_name>
    <role>Study Chair</role>
    <affiliation>Norfolk &amp; Norwich University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanoma and Skin Cancer Trials Coordinator</last_name>
    <phone>+61 3 9903 9022</phone>
    <email>melmart@masc.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles (Cedars-Sinai Medical Center and its Affiliates)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-1804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Mark Faries</last_name>
    </contact>
    <investigator>
      <last_name>Dr Mark Faries</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Michael Lowe</last_name>
    </contact>
    <investigator>
      <last_name>Dr Michael Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Professor Keith Delman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Ferreira</last_name>
    </contact>
    <contact_backup>
      <last_name>Dr. Nicole Kounalakis</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Nicole Kounalakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Adam Berger</last_name>
    </contact>
    <investigator>
      <last_name>Professor Adam Berger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Professor Danielle Bello</last_name>
    </contact>
    <investigator>
      <last_name>Associate Professor Danielle Bello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Stephanie Greco</last_name>
    </contact>
    <investigator>
      <last_name>Dr Stephanie Greco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (The University of Utah)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor John Hynstrom</last_name>
    </contact>
    <investigator>
      <last_name>Professor John Hynstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Public Hospital Bruce</name>
      <address>
        <city>Bruce</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Rebecca Read</last_name>
    </contact>
    <investigator>
      <last_name>Dr Rebecca Read</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Baxter</last_name>
    </contact>
    <investigator>
      <last_name>Dr Krishna Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Fernandez-Peñas</last_name>
      <email>pablo.fernandezpenas@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Prof Pablo Fernandez-Peñas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Spillane</last_name>
    </contact>
    <investigator>
      <last_name>Prof Andrew Spillane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Saw</last_name>
    </contact>
    <investigator>
      <last_name>A/Prof Robyn Saw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof Mark Smithers</last_name>
    </contact>
    <investigator>
      <last_name>Prof Mark Smithers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robina Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4226</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Jennifer Chang</last_name>
    </contact>
    <investigator>
      <last_name>Dr Jennifer Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Henderson</last_name>
    </contact>
    <investigator>
      <last_name>Prof Michael Henderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A/Prof David Gyorki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Frank Bruscino-Raiola</last_name>
    </contact>
    <investigator>
      <last_name>Dr Frank Bruscino-Raiola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Rivard, Dr</last_name>
      <phone>204-787-4156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Cruise</last_name>
      <phone>705-728-9090</phone>
      <phone_ext>45639</phone_ext>
      <email>cruisek@rvh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Renee Hanrahan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Renee Hanrahan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Valerie Francescutti</last_name>
      <phone>905-387-9495</phone>
    </contact>
    <investigator>
      <last_name>Dr. Valerie Francescutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Carolyn Nessim</last_name>
      <email>cnessim@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Carolyn Nessim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Frances Wright</last_name>
      <phone>416-480-4210</phone>
    </contact>
    <investigator>
      <last_name>Dr Frances Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Easson, Dr</last_name>
      <email>Alexandra.Easson@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Lamoureux</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>6258</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Leïla Idrissi Kaïtouni</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>5853</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Dr. Mai-Kim Gervais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1R2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Cindy Boulanger-Gobeil</last_name>
      <email>cindy.boulanger-gobeil@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Dr Cindy Boulanger-Gobeil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOV Istituto Oncologico Veneto IRCCS-Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romina Spina</last_name>
    </contact>
    <investigator>
      <last_name>Dr Simone Mocellin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Ferrari</last_name>
    </contact>
    <investigator>
      <last_name>Prof Alessandro Testori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentina Pala</last_name>
    </contact>
    <investigator>
      <last_name>Dr. Franco Picciotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Heerlen</city>
        <zip>6419</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James van Bastelaar, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Richard Martin</last_name>
    </contact>
    <investigator>
      <last_name>Dr Richard Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Olofsson Bagge</last_name>
      <phone>(0)31-3428207</phone>
      <phone_ext>+46</phone_ext>
      <email>roger.olofsson.bagge@gu.se</email>
    </contact>
    <investigator>
      <last_name>Prof Roger Olofsson Bagge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>29133</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Karolin Isaksson</last_name>
      <email>karolin.isaksson@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Dr Karolin Isaksson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Helens &amp; Knowsley Teaching Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowan Pritchard Jones, Prof</last_name>
      <email>Rowan.PritchardJones@sthk.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital NHS Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR47UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Marc Moncrieff</last_name>
    </contact>
    <investigator>
      <last_name>Professor Marc Moncrieff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

